Home › Funds › Caligan Partners LP › PCVX
Caligan Partners LP position in PCVX
VAXCYTE INC · Health Care
Caligan Partners LP reported holding 2,188,636 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$127.2M, representing 7.44% of its reported portfolio and ranking #3 among its reported holdings. Caligan Partners LP has disclosed PCVX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's PCVX position evolved
Caligan Partners LP first disclosed a stake in PCVX in Q4 2025 at 1,704,815 shares (US$78.7M). The position peaked in Q2 2026 at 2,188,636 shares, worth US$127.2M. Across 3 filings, Caligan Partners LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,188,636 shares valued at US$127.2M — an increase of 127,917 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.70M | $78.66M | New |
| Q1 2026 | 2.06M | $119.75M | Add |
| Q2 2026 | 2.19M | $127.23M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PCVX and 13F data
PCVX (VAXCYTE INC) is a Health Care company. 35 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PCVX
- Jupiter Topco LLC 17.97M sh · $1.04B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M sh · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M sh · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M sh · $249.96M · Q2 2026
- Kynam Capital Management, LP 2.92M sh · $169.88M · Q2 2026
- Paradigm Biocapital Advisors LP 2.13M sh · $123.69M · Q2 2026
- Bellevue Group AG 1.97M sh · $114.63M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M sh · $93.78M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.43M sh · $82.86M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $80.23M · Q2 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held PCVX?
Caligan Partners LP has disclosed PCVX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Caligan Partners LP's current position in PCVX?
As of Q2 2026, Caligan Partners LP holds 2.19M shares of PCVX (VAXCYTE INC), valued at $127.23M, representing 7.44% of its reported portfolio and ranking #3.
Has Caligan Partners LP been buying or selling PCVX?
In the latest 13F filing (Q2 2026), Caligan Partners LP increased its position in PCVX. The position peaked in Q2 2026 at 2.19M shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.